Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!

Find a Clinical Research Study

201 - 207 of 207

ABA3 GVHD ProRx post Allo HACT

This study involves taking the study drug, abatacept, by intravenous (IV) infusion. Along with the study drug, participants will take a either cyclosporine or tacrolimus, and methotrexate, which are standard medications for transplant patients. Participants, 6 years of age and older, will be randomized (placed into a group by chance) by the study team. After being placed into a group, you will receive additional doses of either abatacept (the study drug) or a placebo (an inactive substance). 

Assessing Optically Pumped Magnetoencephalography (MEG)

The goal for this study is to compare performance between a conventional helium based “Cryo_MEG” (magnetoencephalography) system and an investigational optically pumped (‘OP_MEG’) MEG system using brain recordings from typically developing adults. MEG (magnetoencephalography) is a safe, non-invasive brain imaging method used in many forms of research as well as clinical care. MEG is measured by safely wearing a helmet filled with MEG sensors. During the MEG scan, you will be asked to look at a screen, listen to some tones, and push a button. OPM (Optically Pumped Magnetometry), is a brain imaging method that is also worn as a helmet and acquires MEG recording data but differs from conventional “cryo-MEG” because OPM sensors can be positioned closer to the head. This may present an opportunity for better measurement of underlying brain activity.

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R). The KMT2A-R leukemia has come back after treatment (relapsed) or is not responding to treatment (it is refractory). This study involves taking a study drug called SNDX-5613. The study is divided into two phases: one in which the study drug is given in combination with chemotherapy and a phase where the study drug is given alone. The purpose of the study is to test the safety of the study drug with chemotherapy, and how well the treatment regimen works for infants and young children with relapsed or refractory KMT2A-R leukemia.

Vactosertib in Osteosarcoma

This study involves a taking a study drug called vactosertib by mouth. The overall goal of this study is to find out if vactosertib is a safe and effective treatment for adolescents and adults with recurrent, refractory or progressive Osteosarcoma.

Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors

This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment. This study involves taking study drugs called tiragolumab and atezolizumab. These drugs are a type of immunotherapy that try to make the immune system fight cancer. The purpose of the study is to learn more about the safety of tiragolumab in children and to see how well the combination of tiragolumab and atezolizumab works when given to children and adults with these types of tumors. This study has two parts. In Part A, participants will receive tiragolumab. In Part B, participants will receive both tiragolumab and atezolizumab. 

Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids

This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose. 

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’). This study involves taking a drug called uproleselan that is approved for adults with AML but is not yet approved for children. The purpose of the study is to find a safe dose of the study drug in children that can be given with standard chemotherapy without causing severe side effects. 


Pages